Health Care·Biotechnology·$79.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $6.02 | N/A | +12.13% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $6.02 | N/A | +12.13% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook based on current product performance. However, they did not provide specific guidance for future quarters.
Management highlighted the strong performance of their key products.
They expressed confidence in their ongoing research and development efforts.
Regeneron Pharmaceuticals reported a better-than-expected EPS, which contributed to a slight increase in the stock price by 0.23%. The company did not disclose revenue figures or future guidance, leaving investors with limited insights on long-term performance. The positive EPS surprise suggests that the company is managing its costs effectively and performing well in its core areas.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MARRIOTT INTL INC NE Class A
Aug 5, 2019